Y10T436/163333

Field sampling kit and methods for collecting and detecting alkyl methylphosphonic acids

The invention relates to kits and methods of collecting and detecting alkyl methylphosphonic acids from environmental or biological liquids using a sorbent material. The sorbent material may be transported, desorbed and tested for alkyl methylphosphonic acids.

Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently OH, OP(O)(OH)2 or P(O)(OH)2, with the proviso that at least two R are independently selected from P(O)(OH)2 and OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
10024857 · 2018-07-17 · ·

Biomarkers of pancreatic cancer are described, as well as methods using these compounds for detecting pancreatic cancer. The methods can be used to diagnose a patient's health state, or change in health state, or for diagnosing risk of developing or the presence of pancreatic cancer. The method comprises analyzing a sample from a patient to obtain quantifying data for one or more than one of the metabolite markers; comparing the quantifying data to corresponding data obtained for one or more than one reference sample to identify abnormalities in the level of the metabolite marker(s) in the sample; and making a diagnosis if an abnormality is observed. Standards and kits for carrying out the method are also described.

Personal substance detection field test kit

A personal-sized, portable explosive detection field test kit (ETK) and related methods of use. Embodiments of the disclosed ETK include a case having a closing system featuring three levels of closure which retain the case cover securely in a closed position until ready for use, while being easily opened when necessary. The ETK instructions are permanently attached to the case to prevent loss. The case includes retention features which retain the kit components until needed and protects them against loss or damage. The ETK includes one or more test tubes that are color coded and include abbreviated instructions.

Biomarkers for fatty liver disease and methods using the same

The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER

To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker.

The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD.sup.+, and a substance involved in the metabolism of any of these substances.

CHEMICAL VAPORIZATION AND DETECTION OF COMPOUNDS HAVING LOW VOLATILITY

The present disclosure is directed to methods and systems for detecting a chemical substance. The methods and systems include chemically modifying a sample of a substance of interest through combination with a reagent to increase the volatility of the substance of interest. The systems and methods further include performing an analysis of the substance of interest.

TEMPERATURE INFLUENCED CHEMICAL VAPORIZATION AND DETECTION OF COMPOUNDS HAVING LOW VOLATILITY
20170261483 · 2017-09-14 ·

The present disclosure is directed to methods and systems for detecting a chemical substance. The methods and systems include chemically modifying a sample of a substance of interest through combination with a reagent to increase the volatility of the substance of interest. The systems and methods further include performing an analysis of the substance of interest.

Method for the Direct Detection and/or Quantification of at Least One Compound with a Molecular Weight of at Least 200

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently OH, OP(O)(OH)2 or P(O)(OH)2, with the proviso that at least two R are independently selected from P(O)(OH)2 and OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Microfluidic devices

Methods and devices for the interfacing of microchips to various types of modules are disclosed. The technology disclosed can be used as sample preparation and analysis systems for various applications, such as DNA sequencing and genotyping, proteomics, pathogen detection, diagnostics and biodefense. Also disclosed in the present disclosure is a flow through, traveling-wave, bead-beating device which comprises a rotating pole piece, a flow through tube, and a magnetic piece. Rotation of the rotating pole piece may create a magnetic wave down the flow through tube, thereby producing sufficient acceleration of beads through the tube to disrupt or lyse target analytes flowing through the tube.